Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

Vanda Pharmaceuticals has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for its investigational antisense oligonucleotide therapy, VCA-894A. This therapy is designed to treat Charcot-Marie-Tooth disease type 2S (CMT2S), a rare and progressive inherited neurological disorder that primarily affects children and currently lacks effective treatment options. The designation marks a significant regulatory milestone for Vanda, potentially qualifying the company for a valuable priority review voucher upon the drug's eventual marketing approval.

VCA-894A is a 2'-O-methoxyethyl (MOE) phosphorothioate oligonucleotide sodium salt that specifically targets a cryptic splice site variant within the IGHMBP2 gene. The therapy was developed to address a unique variant of CMT2S, an axonal form of the disease with an estimated global prevalence of less than one in one million. CMT2S is characterized by chronic progressive sensory and motor impairment, which can lead to severe disability and the loss of the ability to walk. Because the condition's manifestations primarily affect individuals from birth through age 18, the FDA determined it meets the statutory requirements for a rare pediatric disease.

Mihael H. Polymeropoulos, M.D., President and CEO of Vanda, emphasized that the designation recognizes the high unmet medical need for CMT2S patients and supports the development of a potentially transformative therapy. The FDA's Rare Pediatric Disease Designation is part of a program intended to incentivize the creation of new treatments for serious or life-threatening conditions in children. Under this program, Vanda may become eligible to receive a priority review voucher if VCA-894A meets all statutory requirements and receives marketing approval. These vouchers are highly valued in the pharmaceutical industry as they can be used to expedite the review of a subsequent drug application or sold to another company.

Vanda is currently advancing the development of VCA-894A and intends to maintain close collaboration with the FDA throughout the regulatory process. The company noted that antisense oligonucleotides (ASOs) like VCA-894A have broad potential applicability across various nervous system and systemic disorders. While the therapeutic target for this specific candidate is a variant not yet observed in other patients, the success of the program could validate Vanda's approach to personalized medicine for ultra-rare genetic variants. The company remains focused on addressing high unmet needs through innovative therapies as it moves forward with its clinical and regulatory strategies.